Roche Venture Fund
118
42M
61
5.36
10
0.48
25
- Areas of investment
Summary
Roche Venture Fund appeared to be the VC, which was created in 2002. The main office of represented VC is situated in the Basel. The venture was found in Europe in Switzerland. Roche Venture Fund appeared to be a CVC structure as part of the corporation.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AveXis, Foundation Medicine, Alios BioPharma. Among the most popular fund investment industries, there are Pharmaceutical, Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
We also calculated 3 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Roche Venture Fund, startups are often financed by SR One, Apple Tree Partners, Pfizer Venture Investments. The meaningful sponsors for the fund in investment in the same round are 5AM Ventures, Lilly Ventures, Ysios Capital. In the next rounds fund is usually obtained by SR One, Pfizer Venture Investments, Lilly Ventures.
Speaking about the real fund results, this VC is 10 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Roche Venture Fund performs on 4 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2017.
Investments analytics
Analytics
- Total investments
- 118
- Lead investments
- 10
- Exits
- 25
- Rounds per year
- 5.36
- Follow on index
- 0.48
- Investments by industry
- Biotechnology (107)
- Health Care (61)
- Therapeutics (48)
- Medical (29)
- Pharmaceutical (27) Show 26 more
- Investments by region
-
- United States (80)
- United Kingdom (12)
- Spain (5)
- Denmark (2)
- Latvia (3) Show 7 more
- Peak activity year
- 2018
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 85M
- Group Appearance index
- 0.98
- Avg. company exit year
- 9
- Avg. multiplicator
- 6.90
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Millendo Therapeutics | 05 Jan 2016 | Biotechnology, Life Science, Therapeutics | Early Stage Venture | 62M | United States, Ann Arbor, Michigan |
| Cour Pharmaceuticals Development | 30 Jan 2024 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 105M | United States, Illinois, Elmhurst |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.